Skip to content

Released May 15, 2024, after the close

10-Q filed May 15, 2024, 45 days after period end · 0000950170-24-060400

Q1 2024 · 10-Q
Revenue$140.00K−37.2% vs Q1 2023−37.2% vs Q4 2023
Net Income-$12.67MN/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.24N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$13,982,000N/M
Operating Cash Flow$5,938,000N/M
Margins · derived
Operating margin-9987.1%−3607.3 pt vs Q1 2023
Net margin-9049.3%−3085.2 pt vs Q1 2023

What the release said

The release

Same quarter

MetricQ1 2024Q1 2023Q1 2022Q1 2021
Revenue$140.00K$223.00K$247.00K$7.30M
Net Income-$12.67M-$13.30M-$32.80M-$19.40M
EPS Diluted-$0.24-$0.25-$1.01-$0.66

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR